|Day's Range||33.95 - 34.26|
|52 Week Range||25.25 - 36.82|
|PE Ratio (TTM)||24.24|
|Dividend & Yield||1.03 (3.03%)|
|1y Target Est||N/A|
A person in Germany treated with Roche Holding AG’s new multiple sclerosis drug Ocrevus has been diagnosed with an often-deadly brain infection after switching from another medication earlier this year, the Swiss drugmaker said on Wednesday. Roche said it was investigating a case of Progressive Multifocal Leukoencephalopathy (PML) in a patient previously being treated for three years with Biogen Inc's Tysabri and who had received a single dose of Ocrevus in April. Roche is trying to determine the source of the illness but MS drugs that suppress the immune system can increase the risk of serious infections.
Roche Holding AG (RHHBY) announced new retrospective data analyses for idiopathic pulmonary fibrosis (IPF) drug, Esbriet.
In 1Q17, Amgen’s (AMGN) Nplate generated revenues of ~$154 million, which reflected a year-over-year growth rate of 9%.